Behavioral effects of Flibanserin (BIMT 17)

Pharmacology Biochemistry and Behavior

Volumn 64, Issue 1, 1999, Pages 137-146

  Borsini, Franco ^a   Brambilla, Alessandro ^a   Grippa, Nicoletta ^a   Pitsikas, Nikolaos ^a  

^a Boehringer Ingelheim Italia SpA   (Italy)

Author keywords

Elevated plus maze; Flibanserin; Hypermotility; Light dark exploratory test; Motor activity; Mouse; Rat; Stereotypy; Stress induced hyperthermia; Water maze

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; APOMORPHINE; BUSPIRONE; DIAZEPAM; FLIBANSERIN; LORAZEPAM; N ALLYLNORMETAZOCINE; SEROTONIN 2A AGONIST;

ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; FORCED SWIMMING TEST; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BENZIMIDAZOLES; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; MALE; MAZE LEARNING; MICE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; STEREOTYPED BEHAVIOR; STRESS, PSYCHOLOGICAL;

EID: 0032834590     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00072-6     Document Type: Article

References (70)

1. 1A receptor agonists on patterns of rat motor activity in relation to effects on forebrain monoamine synthesis. Pharmacol. Toxicol. 72:1993;398-406.
2. 2 receptor antagonist properties, on male rat sexual behaviour. Eur. J. Pharmacol. 255:1994;131-137.
3. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 40:1991;399-401.
4. 2 agonist DOI. Eur. J. Pharmacol. 161:1989;45-51.
5. 1A receptor agonist with anxiolytic activity. Eur. J. Pharmacol. 344:1998;127-135.
6. Berendsen H.H.G., Broekkamp C.L.E. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br. J. Pharmacol. 101:1990;667-673.
7. 1A syndrome Pharmacol. Biochem. Behav. 57:1997;897-908.
8. Boess F.G., Martin I.L. Molecular biology of 5-HT receptors. Neuropharmacology. 33:1994;275-317.
9. 1A receptors. Critical aspects CNS Spectrums. 3:1998;17-38.
10. Borsini F., Brambilla A., Ceci A., Cesana R., Giraldo E., Ladinsky H., Monferini E., Turconi M. Flibanserin. Drugs Future. 23:1998;9-16.
11. 2A antagonist, directly activates postsynaptic 5-HT inhibitory responses in the cortex. Naunyn Schmiedebergs Arch. Pharmacol. 352:1995;283-290.
12. Borsini F., Cesana R., Kelly J., Leonard B.E., Mc Namara M., Richards J., Seiden L. BIMT 17. A putative antidepressant with a fast onset of action? Psychopharmacology (Berlin). 134:1997;378-386.
13. Borsini F., Lecci A., Volterra G., Meli A. A model to measure anticipatory anxiety? Psychopharmacology (Berlin). 98:1989;207-211.
14. Borsini F., Meli A. The forced swimming test. its contribution to the understanding of the mechanisms of action of antidepressants Adv. Biosci. 77:1990;63-76.
15. 1A agonists on stress-induced deficit in open field locomotor activity of rats. Evidence that this model identifies anxiolytic-like activity Neuropharmacology. 28:1989;471-476.
16. 1A receptors Br. J. Pharmacol. 105:1992;720-726.
17. Cassel J.C., Jeltsch H. Serotonergic modulation of cholinergic function in the central nervous system. Cognitive implications Neuroscience. 69:1995;1-41.
18. Cervo L., Grignaschi G., Samanin R. The role of the mesolimbic dopaminergic system in the desipramine effect in the forced swimming test. Eur. J. Pharmacol. 178:1990;129-133.
19. Cervo L., Samanin R. Evidence that dopamine mechanisms in the nucleus accumbens are selectively involved in the effect of desipramine in the forced swimming test. Neuropharmacology. 26:1987;1469-1472.
20. Cervo L., Samanin R. Repeated treatment with imipramine and amitriptyline reduced the immobility of rats in the swimming test by enhancing dopamine mechanisms in the nucleus accumbens. J. Pharm. Pharmacol. 40:1988;155-156.
21. Cesana R., Ciprandi C., Borsini F. The effect of BIMT 17, a new potential antidepressant, in the forced swimming test in mice. Behav. Pharmacol. 6:1995;688-694.
22. Cole J.C., Rodger R.J. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test. Comparison with haloperidol Psychopharmacology (Berlin). 114:1994;288-296.
23. 1A antagonist, WAY 100635. Psychopharmacology (Berlin). 132:1997;35-42.
24. Costall B., Marsden C.D., Naylor R.J., Pycock C.J. Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramydal and mesolimbic nuclei. Brain Res. 123:1977;89-111.
25. Costall B., Naylor R.J. The role of telencephalic dopaminergic system in the mediation of apomorphine-stereotyped behaviour. Eur. J. Pharmacol. 24:1973;8-24.
26. Costall B., Naylor R.J. Extrapyramidal and mesolimbic involvement with the stereotypic activity of d- and l-amphetamine. Eur. J. Pharmacol. 25:1974;121-129.
27. 4 receptor antagonists to modify drug induced disinhibitory effects in the mouse light/dark test. Br. J. Pharmacol. 122:1997;1105-1118.
28. Cox D.R., Oakes D. Analysis of survival data. 1984;Chapman and Hall, London.
29. 2 receptors. Psychopharmacology (Berlin). 93:1987;502-506.
30. 1A ligands in the elevated X-maze and effects of dorsal raphe lesions. Psychopharmacology (Berlin). 106:1992;484-490.
31. 1A full agonist, in the elevated plus-maze and social interaction test. Drug Dev. Res. 32:1994;183-190.
32. D'Aquila P., Monleon S., Borsini F., Brain P., Willner P. Anti-anhedonic actions of the novel serotonergic agent BIMT-17, a potential rapidly-acting antidepressant. Eur. J. Pharmacol. 340:1997;339-340.
33. 1A receptor agonists. Recent developments and controversial issues Psychopharmacology (Berlin). 121:1995;1-26.
34. Evenden J.L., Ängeby-Möller K. Effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on locomotor activity and rearing of mice and rats. Psychopharmacology (Berlin). 102:1990;485-491.
35. File S.E., Andrews N. Low but not high doses of buspirone reduce the anxiogenic effects of diazepam withdrawal. Psychopharmacology (Berlin). 105:1991;578-582.
36. Gao B., Cutler M.G. Effects of acute and subchronic administration of ritanserin on the social behaviour of mice. Neuropharmacology. 32:1993;265-272.
37. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders. more than 30 years of research Pharmacol. Ther. 65:1995;319-395.
38. 1A agonist, S20244, and its enantiomers in mice. Neuroreport. 3:1992;84-86.
39. Groenink L., van der Gugten J., Zethof T.J.J., van dr Heydn J.A.M., Olivier B. Neuroendocrine effects of diazepam and flesinoxan in the stress-induced hyperthermia in mice. Pharmacol. Biochem. Behav. 54:1996;249-253.
40. Handley S.L. 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol. Ther. 66:1995;103-148.
41. Hutson P.H., Donohoe T.P., Curzon G. Nurochemical and behavioural evidence for an agonist action of 1-[2-(4-aminophenyl)ethyl]-4-(3-trifluoromethylphenyl)piperazine (LY 165163) at central 5-HT receptors. Eur. J. Pharmacol. 138:1987;215-223.
42. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data. 1980;John Wiley & Sons, Inc, New York.
43. Kant G.J., Wylie R.M., Chu K., Ghosh S. Effects of the serotonin agonists 8-OH-DPAT, buspirone and DOI on water maze performance. Pharmacol. Biochem. Behav. 59:1998;729-745.
44. 2A/2C antagonist anxiolytics. II. Drug discrimination and behavioural observation studies in rats. J. Pharmacol. Exp. Ther. 282:1997;747-759.
45. 2A/2C antagonist anxiolytics. I. Antipunishment effects in the pigeon. J. Pharmacol. Exp. Ther. 276:1996;388-397.
46. Klint T. Effects of 8-OH-DPAT and buspirone in a passive avoidance test and in the elevated plus-maze test in rats. Behav. Pharmacol. 2:1991;481-489.
47. Lakoski J.M., Aghajanian G.K. Effect of ketanserine on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology. 24:1985;265-273.
48. Lecci A., Borsini F., Mancinelli A., D'Aranno V, Stasi M.A., Volterra G., Meli A. Effects of serotonergic drugs on stress-induced hyperthermia (SIH) in mice. J. Neural Transm. 82:1990;219-230.
49. Lister R.G. Ethologically-based animal models of anxiety disorders. Pharmacol. Ther. 46:1990;321-340.
50. McNaughton N., Morris R.G.M. Buspirone produces a dose-related impairment in spatial navigation. Pharmacol. Biochem. Behav. 43:1992;167-171.
51. 1A ligands, 8-OH-DPAT and MDL 73005EF, in mice. Neuroreport. 1:1990;267-270.
52. 1A agonists on locomotor and investigatory behaviors in rats differ from those of hallucinogens. Psychopharmacology (Berlin). 98:1989;321-329.
53. 1A-receptor agonists show an anxiogenic-like profile in the elevated plus maze. Bevan P., Cools A.R., Archer T. Behavioural pharmacology of 5-HT. 1989;371-375 Erlbaum, Hillsdale, NJ.
54. 1A selective ligand and its effects in animal models of anxiety. Comparison with buspirone, 8-OH-DPAT and diazepam Br. J. Pharmacol. 99:1990;343-349.
55. 1A receptors on the exploratory activity of rats in the elevated plus-maze. Psychopharmacology (Berlin). 107:1992;135-139.
56. Olivier B., Molewijk E., van Oorschot R., van der Poel G., Zethof T., van der Heydn J., Mos J. New animal models of anxiety. Eur. Neuropsychopharmacol. 4:1994;93-102.
57. Pellow S., Chopin P., File S., Briley M. Valutation of open-closed arm entries in an elevated plus-maze as a measure of anxiety in the rats. J. Neurosci. Methods. 14:1985;149-167.
58. Pellow S., Johnston A., File S.E. Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes and interactions with yohimbine and FG7142 using the elevated plus-maze test in the rat. J. Pharm. Pharmacol. 39:1987;917-928.
59. 3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task. Pharmacol. Biochem. Behav. 47:1994;95-99.
60. Protais P., Chagraoui A., Arbaoui, Mocaër E. Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents. Eur. J. Pharmacol. 271:1994;167-177.
61. 1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats. Behav. Pharmacol. 8:1997;699-706.
62. Rodgers R.J., Johnson N.J.T., Norton S.J., Cole J.C. Effects of ritanserin and 1-(2,5.dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the murine elevated plus-maze test of anxiety. An ethological study J. Psychopharmacol. 9:1995;38-42.
63. 1A receptors in the rat brain. Synapse. 29:1998;392-405.
64. 1A receptors play an important role in modulation of behavior of rats in a two-compartment black and white box. Behav. Pharmacol. 7:1996;788-797.
65. 2A receptors in antipsychotic activity. Life Sci. 56:1995;2209-2222.
66. 7 serotonin receptor subtype. J. Biol. Chem. 268:1993;18200-18204.
67. Szewczak M.R., Corbett R., Rush D.K., Wilmot C.A., Conway P.G., Strupczewski J.T., Cornfeldt M. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J. Pharmacol. Exp. Ther. 274:1995;1404-1413.
68. Treit D., Robinson A., Rotzinger S., Pesold C. Anxiolytic effects of serotonergic interventions in the shock-probe burying test and the elevated plus-maze test. Behav. Brain Res. 54:1993;23-34.
69. 1 receptor and of catecholaminergic system in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur. J. Pharmacol. 106:1984;271-282.
70. Van Wijngaarden I., Tulp M.T.M., Soudijn W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. 188:1990;301-312.